

Cambridge University Press & Assessment
978-1-009-30543-3 — Marijuana and Madness
3rd Edition
Edited by Deepak Cyril D'Souza , David Castle , Sir Robin Murray
Frontmatter
[More Information](#)

Marijuana and Madness

Cambridge University Press & Assessment
978-1-009-30543-3 — Marijuana and Madness

3rd Edition

Edited by Deepak Cyril D'Souza , David Castle , Sir Robin Murray

Frontmatter

[More Information](#)

Marijuana and Madness

Third Edition

Edited by

Deepak Cyril D'Souza

Yale University School of Medicine

David J. Castle

University of Tasmania

Sir Robin M. Murray

Institute of Psychiatry



CAMBRIDGE
UNIVERSITY PRESS

Cambridge University Press & Assessment
978-1-009-30543-3 — Marijuana and Madness
3rd Edition
Edited by Deepak Cyril D'Souza , David Castle , Sir Robin Murray
Frontmatter
[More Information](#)



Shaftesbury Road, Cambridge CB2 8EA, United Kingdom
One Liberty Plaza, 20th Floor, New York, NY 10006, USA
477 Williamstown Road, Port Melbourne, VIC 3207, Australia
314–321, 3rd Floor, Plot 3, Splendor Forum, Jasola District Centre, New Delhi – 110025, India
103 Penang Road, #05-06/07, Visioncrest Commercial, Singapore 238467

Cambridge University Press is part of Cambridge University Press & Assessment,
a department of the University of Cambridge.

We share the University’s mission to contribute to society through the pursuit of
education, learning and research at the highest international levels of excellence.

www.cambridge.org
Information on this title: www.cambridge.org/9781009305433
DOI: 10.1017/9781108943246

© Cambridge University Press & Assessment 2023

This publication is in copyright. Subject to statutory exception and to the provisions
of relevant collective licensing agreements, no reproduction of any part may take
place without the written permission of Cambridge University Press & Assessment.

First edition published 2004
Second edition published 2012
Third edition published 2023

Printed in Great Britain by Ashford Colour Press Ltd.

A catalogue record for this publication is available from the British Library.

Library of Congress Cataloging-in-Publication Data
Names: D'Souza, Deepak Cyril, editor. | Castle, David J., editor. | Murray, Robin M., 1944- editor.
Title: Marijuana and madness / edited by Deepak D'Souza, David Castle, Sir Robin Murray.
Description: Third edition. | Cambridge, United Kingdom ; New York : Cambridge University Press, 2023. |
Includes bibliographical references and index.
Identifiers: LCCN 2022053404 (print) | LCCN 2022053405 (ebook) | ISBN 9781108837835 (hardback) |
ISBN 9781009305433 (paperback) | ISBN 9781108943246 (epub)
Subjects: MESH: Marijuana Abuse–psychology | Marijuana Smoking–adverse effects | Cannabinoids–pharmacology |
Mental Disorders–complications
Classification: LCC RC568.C2 (print) | LCC RC568.C2 (ebook) | NLM WM 276 | DDC 362.29/5–dc23/eng/20230118
LC record available at <https://lcn.loc.gov/2022053404>
LC ebook record available at <https://lcn.loc.gov/2022053405>
ISBN 978-1-009-30543-3 Paperback

Cambridge University Press & Assessment has no responsibility for the persistence
or accuracy of URLs for external or third-party internet websites referred to in this
publication and does not guarantee that any content on such websites is, or will
remain, accurate or appropriate.

.....

Every effort has been made in preparing this book to provide accurate and up-to-date information that is in accord with accepted standards
and practice at the time of publication. Although case histories are drawn from actual cases, every effort has been made to disguise the
identities of the individuals involved. Nevertheless, the authors, editors, and publishers can make no warranties that the information
contained herein is totally free from error, not least because clinical standards are constantly changing through research and regulation. The
authors, editors, and publishers therefore disclaim all liability for direct or consequential damages resulting from the use of material
contained in this book. Readers are strongly advised to pay careful attention to information provided by the manufacturer of any drugs or
equipment that they plan to use.

Contents

List of Contributors vii

Preface xi

Part I Pharmacology of Cannabis and the Endocannabinoid System

1 How Cannabis Works in the Brain 1

Michelle Murphy Green and Ken Mackie

2 The Function of the Endocannabinoid System 12

Nathan D. Winters and Sachin Patel

3 Synthetic Cannabinoids 21

Liana Fattore and Matteo Marti

Part II The Changing Face of Cannabis

4 The Epidemiology of Cannabis Use and Cannabis Use Disorder 31

Deborah Hasin

5 Is Cannabis Becoming More Potent? 43

Tom P. Freeman and Sam Craft

6 Policy Implications of the Evidence on Cannabis Use and Psychosis 51

Wayne Hall and Louisa Degenhardt

Part III Cannabis and the Brain

7 The Impact of Adolescent Exposure to Cannabis on the Brain: A Focus on Animal Studies 61

Erica Zamberletti and Tiziana Rubino

8 The Impact of Cannabis Exposure on the Adolescent Brain: Human Studies and Translational Insights 68

Jacqueline-Marie Ferland, Alexandra Chisholm, and Yasmin L. Hurd

9 Cannabis and Cognition: An Update on Short- and Long-term Effects 76

Lisa-Marie Greenwood, Valentina Lorenzetti, and Nadia Solowij

10 Is There a Cannabis-Associated Psychosis Sub-type? Lessons from Biological Typing in the B-SNIP Project and Implications for Treatment 91

Godfrey D. Pearlson and Matcheri S. Keshavan

Part IV Cannabis, Anxiety, and Mood

11 Cannabis and Anxiety 107

Grace Lethbridge, Beth Patterson, and Michael Van Ameringen

12 Cannabis Consumption and Risk of Depression and Suicidal Behaviour 120

Gabriella Gobbi

13 Cannabis and Bipolar Disorder 128

Jairo Vinícius Pinto and Mauren Letícia Ziak

Part V Cannabis and Psychosis

14 Cannabis and Psychosis Proneness 139

Rajiv Radhakrishnan, Shubham Kamal, Sinan Guloksuz, and Jim van Os

15 Which Cannabis Users Develop Psychosis? 148

Edoardo Spinazzola, Marta Di Forti, and Robin M. Murray

16 Cannabis Causes Positive, Negative, and Cognitive Symptoms and Produces Impairments in Electrophysiological Indices of Information Processing 156

Ashley M. Schnakenberg Martin, Mohini Ranganathan, and Deepak Cyril D'Souza

Contents

Part VI Cannabinoids and
Schizophrenia: Aetiopathology and
Treatment Implications

- 17 **Does Cannabis Cause Psychosis? The Epidemiological Evidence** 167
Emmet Power, Colm Healy, Robin M. Murray, and Mary Cannon
- 18 **Post-mortem Studies of the Brain Cannabinoid System in Schizophrenia** 178
Suresh Sundram, Brian Dean, and David Copolov
- 19 **The Endocannabinoid System in Schizophrenia** 189
Paul D. Morrison
- 20 **Cannabidiol as a Potential Antipsychotic** 200
F. Markus Leweke and Cathrin Rohleder
- 21 **Genetic Explanations for the Association between Cannabis and Schizophrenia** 216
Sarah M. C. Colbert and Emma C. Johnson

Part VII Cannabis and Its Impact
on Schizophrenia

- 22 **The Acute Effects of Cannabinoids in Patients with Psychotic Illness** 225
Suhas Ganesh, Cécile Henquet, R. Andrew Sewell, Rebecca Kuepper, Mohini Ranganathan, and Deepak Cyril D'Souza
- 23 **Cannabis and the Long-term Course of Psychosis** 240
Tabea Schoeler
- 24 **Treating Cannabis Use in Schizophrenia and Other Psychotic Disorders** 246
Alexandria S. Coles, Ashley E. Kivlichan, David J. Castle, and Tony P. George

Part VIII Special Topics

- 25 **Pre-natal Cannabis Exposure: Associations with Development and Behaviour** 267
Sarah E. Paul, Cynthia E. Rogers, and Ryan Bogdan
- 26 **Cannabis Use and Violence** 279
Giulia Trotta, Paolo Marino, Victoria Rodriguez, Robin M. Murray, and Evangelos Vassos
- 27 **Cannabis Withdrawal** 285
Jane Metrik and Kayleigh N. McCarty
- 28 **Cannabis and Addiction** 299
H. Valerie Curran, Will Lawn, and Tom P. Freeman
- 29 **Tobacco Use among Individuals with Cannabis Use: Insights into Co-use and Why It Matters for People with Psychosis** 310
Rachel A. Rabin, Erin A. McClure, and Tony P. George
- 30 **Cannabis Addiction Genetics** 321
Suhas Ganesh and Arpana Agrawal
- 31 **Snoozing on Pot: Cannabis and Sleep** 333
Patrick D. Skosnik and Toral S. Surti
- 32 **Cannabinoids as Medicines: What the Evidence Says and What It Does Not Say** 346
Marco De Toffol, Elena Dragioti, Andre Ferrer Carvalho, and Marco Solmi

Index 357
Colour plates are to be found between pages 188 and 189

Contributors

Arpana Agrawal, PhD
Washington University School of Medicine, USA

Ryan Bogdan, PhD
Washington University in St. Louis, USA

Mary Cannon, MD, PhD
RCSI University of Medicine and Health Sciences,
Ireland

Andre Ferrer Carvalho, MD, PhD
Deakin University, Australia

David J. Castle, MD
University of Tasmania, Australia

Alexandra Chisholm, PhD
Icahn School of Medicine, USA

Sarah M. C. Colbert, PhD
Washington University School of Medicine, USA

Alexandria S. Coles, MSc
University of Toronto, Canada

David Copolov, MD, PhD
Monash University, Australia

Sam Craft, PhD
University of Bath, UK

H. Valerie Curran, PhD
University College London, UK

Marco De Toffol, MD
Veris Delli Ponti Scorrano Hospital, Italy

Brian Dean, PhD
Florey Institute of Neuroscience and Mental Health,
Australia

Louisa Degenhardt, PhD
University of New South Wales, Australia

Marta Di Forti, MD, PhD
King's College London, UK

Elena Dragioti, PhD
Linköping University, Sweden

Deepak Cyril D'Souza, MD
Yale University School of Medicine, USA

Liana Fattore, PhD
CNR Institute of Neuroscience-Cagliari,
Italy

Jacqueline-Marie Ferland, PhD
Icahn School of Medicine, USA

Tom P. Freeman, PhD
University of Bath, UK

Suhas Ganesh, MD
Yale University School of Medicine, USA

Tony P. George, MD, FRCPC
University of Toronto, Canada

Gabriella Gobbi, MD, PhD
McGill University, Canada

Michelle Murphy Green, MS
Indiana University, USA

Lisa-Marie Greenwood, PhD
Australian National University, Australia

Sinan Guloksuz, MD, PhD
Maastricht University Medical Center, The
Netherlands

Wayne Hall, PhD
University of Queensland, Australia

Deborah Hasin, PhD
Columbia University, USA

List of Contributors

Colm Healy, PhD RCSI University of Medicine and Health Sciences, Ireland	Jane Metrik, PhD Brown University School of Public Health, USA
Cécile Henquet, PhD Maastricht University, The Netherlands	Paul D. Morrison, MD, PhD Argyll and Bute Hospital, UK
Yasmin L. Hurd, PhD Icahn School of Medicine, USA	Robin M. Murray, MD King’s College London, UK
Emma C. Johnson, PhD Washington University School of Medicine, USA	Jim van Os, MD, PhD Utrecht University Medical Center, The Netherlands
Shubham Kamal, MBBS Yale University School of Medicine, USA	Sachin Patel, MD, PhD Northwestern University, USA
Matcheri S. Keshavan, MD Harvard Medical School, USA	Beth Patterson, BScN, BEd, MSc McMaster University, Canada
Ashley E. Kivlichan, BS University of Toronto, Canada	Sarah E. Paul, MA Washington University in St. Louis, USA
Rebecca Kuepper, PhD Maastricht University, The Netherlands	Godfrey D. Pearlson, MD Yale University School of Medicine, USA
Will Lawn, PhD King’s College London, UK	Jairo Vinícius Pinto, MD, PhD University Hospital, Universidade Federal de Santa Catarina, Brazil
Grace Lethbridge, BHSc McMaster University, Canada	Emmet Power, MB BCH RCSI University of Medicine and Health Sciences, Ireland
F. Markus Leweke, MD MA University of Sydney, Australia	Rachel A. Rabin, PhD McGill University, Canada
Valentina Lorenzetti, PhD Australian Catholic University, Australia	Rajiv Radhakrishnan, MD Yale University School of Medicine, USA
Ken Mackie, MD Indiana University, USA	Mohini Ranganathan, MD Yale University School of Medicine, USA
Paolo Marino, MD King’s College London, UK	Victoria Rodriguez, MD King’s College of London, UK
Matteo Marti, PhD University of Ferrara, Italy	Cynthia E. Rogers, MD Washington University School of Medicine, USA
Ashley M. Schnakenberg Martin, PhD Yale University School of Medicine, USA	Cathrin Rohleder, PhD University of Sydney, Australia
Kayleigh N. McCarty, PhD VA Boston Healthcare System	Tiziana Rubino, PhD University of Insubria, Italy
Erin A. McClure, PhD Medical University of South Carolina (MUSC), USA	

Cambridge University Press & Assessment
978-1-009-30543-3 — Marijuana and Madness
3rd Edition
Edited by Deepak Cyril D'Souza , David Castle , Sir Robin Murray
Frontmatter
[More Information](#)

List of Contributors

Tabea Schoeler, PhD University of Lausanne, Switzerland	Toral S. Surti, MD, PhD Yale University School of Medicine, USA
R. Andrew Sewell, MD† Yale University School of Medicine, USA	Giulia Trotta, MD King’s College London, UK
Patrick D. Skosnik, PhD Yale University School of Medicine, USA	Michael Van Ameringen, MD, FRCPC McMaster University, Canada
Marco Solmi, MD, PhD University of Ottawa, Canada	Evangelos Vassos, MD King’s College London, UK
Nadia Solowij, PhD University of Wollongong, Australia	Nathan D. Winters, PhD Vanderbilt University School of Medicine, USA
Edoardo Spinazzola, MD King’s College London, UK	Erica Zamberletti, PhD University of Insubria, Italy
Suresh Sundram, MBBS, PhD Monash University, Australia	Mauren Letícia Ziak, MD, MSc Faculdade Pequeno Príncipe, Brazil

Preface

Since the first and second editions of *Marijuana and Madness* were published in 2004 and 2012, respectively, interest in cannabis, cannabinoids, and mental health has continued to grow. Since the last edition of this book, the landscape of cannabis has changed. The strength of cannabis has increased, with a number of highly potent forms of cannabis-derived products becoming available; cannabis laws have been liberalized in many jurisdictions; and the large-scale commercialization of cannabis has begun. In parallel, the science of the endocannabinoid system has advanced. Given the changes in legality, availability, and potency of cannabis, the adverse consequences of cannabis are likely to be seen more frequently in contemporary society than in studies conducted decades ago. Indeed, the topic has moved from being of interest mainly to specialists in psychosis and addiction to being a public mental health concern. The third edition of this book addresses these changes and more. The first edition had 13 chapters and the second edition had 21 chapters. This third edition has 32 chapters, with updates to core chapters from the first and second editions and a number of entirely new chapters. Consistent with the growing awareness of the consequences of cannabis exposure, the scope of the book has expanded beyond psychosis, to include bipolar disorder, depression, anxiety disorders, and cannabis use disorder.

The first part of the book covers the pharmacology of cannabis and the endocannabinoid system. Mackie reviews how cannabis works in the brain, followed by an overview of the endocannabinoid system (Winters and Patel), and synthetic cannabinoids (Fattore and Marti). These chapters set the stage for chapters addressing some of the most pressing concerns about the acute and chronic consequences of cannabis use.

Addressing the changing face of cannabis, Hasin provides an overview of the epidemiology of cannabis use and cannabis use disorder, followed by a review of the changing potency of cannabis (Freeman and

Craft). Then, Hall and Degenhardt review the health policy implications of the relationship between cannabis and mental illness.

Any theory associating exposure to cannabis with long-term negative mental health consequences needs to have biological plausibility; that is, there needs to be a plausible underlying biological mechanism. If the endocannabinoid system is involved in adolescent brain development, then perturbation of this system at critical periods of brain development may have far reaching consequences. The impact of cannabis exposure on the adolescent brain is discussed in animals (Zamberletti and Rubino) and humans (Ferland et al.). Greenwood and colleagues review the short- and long-term effects of cannabis on cognition. As cannabis is being increasingly used by women during pregnancy, Paul et al. review the impact of prenatal cannabis exposure on neurodevelopment and behaviour.

The relationship between cannabis and anxiety (Lethbridge et al.), depression and suicidal behaviour (Gobbi), and bipolar disorder (Pinto and Zia) is covered in the ensuing section, teasing apart cause and effect and considering implications for treatment.

Radhakrishnan et al. review the evidence on the relationship between cannabis and psychosis proneness. Going further, Spinazzola et al. discuss factors that might predispose cannabis using individuals to psychosis and suggest that the link between cannabis use and schizophrenia is unlikely to be just the result of a genetic predisposition, it is more likely the result of an interplay between genes and the environment. Martin-Schnakenberg and colleagues address experimental and other evidence showing that cannabis and cannabinoids are linked to positive, negative, and cognitive symptoms, as well as producing impairments in electrophysiological indices of information processing.

Extending the cannabis/psychosis theme, Power and colleagues address the important and contentious

Preface

question in the field as to whether cannabis actually causes schizophrenia. Colbert and Johnson review genetic explanations for the link between cannabis and schizophrenia. Pearlson and Keshavan provide evidence suggesting the possibility of a cannabis associated psychosis subtype.

Beyond the hypothesis linking exposure to exocannabinoids such as cannabis to psychosis, there is emerging evidence that the endocannabinoid system may be altered in schizophrenia. Sundram et al. and Morrison review the post-mortem, animal and in-vivo evidence on the state of the endocannabinoid system in schizophrenia.

One of the vexing clinical conundrums is the discrepancy between the “benefits” of cannabis reported by users and the negative consequences on the course and expression of schizophrenia observed by clinicians. Ganesh et al. review the acute effects of cannabis and cannabinoids in people with psychotic illness, whilst Schoeler provides an overview of the impact of cannabis on the long-term course of schizophrenia.

Several new chapters addressing emerging issues relevant to cannabis use have been added. Trotta et al. review the growing interest in the association between cannabis exposure and violence, while a number of chapters focus on cannabis addiction. Curran and colleagues review the neurobiology, expression, and treatment of cannabis use disorder, and in related

chapters Metrik and McCarty review the characteristics, course, and treatment of cannabis withdrawal syndrome, while Ganesh and Agrawal provide a synopsis of the genetics of cannabis addiction. In a clinically-focused chapter, Coles et al. address potential treatments for cannabis misuse in individuals with psychosis.

Given that cannabis is often used with tobacco, especially in Europe, understanding the relationship between the two is important. Rabin et al. review the interactions between cannabis and withdrawal. There is increasing recognition that people use cannabis to facilitate sleep, and that the endocannabinoid system may be involved in sleep; Skosnik and Surti assess the role of cannabis and the endocannabinoid system in sleep.

Lastly, beyond the recreational use of cannabis, there is increasing interest in the ‘medical use’ of cannabis. Leweke and Rohleder address the intriguing possibility that cannabidiol (CBD) may have beneficial effects in schizophrenia, while De Toffol and colleagues review the evidence on the ‘medical use’ of cannabis.

As editors, we are excited at the richness of the material provided to us by the contributors, all leaders in their field. We hope that readers will be likewise impressed at the progress that has been made in our understanding of the relationship between cannabis, cannabinoids, and neuropsychiatric disorders.